API
< Back to all clusters
[BUSINESS] · United States · 7 sources

started · updated

Eli Lilly raises revenue guidance following strong weight loss drug sales

Eli Lilly has increased its full-year 2026 revenue guidance to a range between $91 billion and $92 billion, up from a previous estimate of $85 billion to $87 billion. This adjustment follows a third-quarter earnings report that surpassed analyst expectations, driven largely by the company’s GLP-1 agonist portfolio.

Diabetes treatment Mounjaro generated $10.72 billion in worldwide revenue for the quarter, representing 65% growth. Zepbound, used for obesity, posted $5.35 billion in quarterly revenue, a 49% increase year-over-year. While the newly launched oral obesity pill Foundayo reported $184 million in sales, it fell short of the approximately $229 million expected by analysts.

CEO Dave Ricks noted significant potential for market expansion, stating that current obesity treatment access affects only 3% to 10% of eligible patients in the United States. The company currently holds a 63% share of the U.S. obesity and diabetes drug market.

Entities

Berkshire Hathaway · Dave Ricks · David Ricks · Eli Lilly · Eli Lilly and Company · Foundayo · Mounjaro · Samsung Electronics · Zepbound

Claims

What the coverage asserts, and how many sources carry each claim.